Navigation Links
Genzyme Files Applications for Approval of Mozobil in the United States and Europe
Date:6/17/2008

han drug status in the United States and European Union and the pivotal trials have undergone Special Protocol Assessment by the FDA and Protocol Assistance by the EMEA. Genzyme has been developing Mozobil since its acquisition of AnorMED, Inc. in 2006.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme(R) and AnorMED(R) are registered trademarks of Genzyme Corporation or its subsidiaries. Mozobil(TM) is an unregistered trademark of Genzyme Corporation or its subsidiaries. All rights reserved.

This press release contains forward-looking statements, including the statements regarding: the anticipated timing of product approvals in the U.S. and Europe, the anticipated timing of filing additional applications for approval in other countries, the potential adoption of Mozobil in the marketplace, the potential benefits to different types of patients, commercial launch plans and Mozobil's potential use in other therapeutic applications. T
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management
2. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
3. Genzyme Reports Strong First-Quarter Growth
4. Genzyme to Build New R&D Center in Beijing
5. Genzyme Provides Update on Myozyme(R) Manufacturing
6. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
7. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
8. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
11. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 1, 2015 R-Japan Co.,Ltd. obtained the license of ... Regenerative Medicine from the Ministry of Health, Labour and Welfare ... The fact that R- Japan ... auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May ... to provide stem cell manufacturing service to medical institutions. As ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... on developing therapeutics that address unmet medical needs ... George Elston will present at the Cantor ... July 8, 2015Time: , 4:45 PM EDTLocation: , ... & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed to be ... (including shares of unvested restricted stock). On June 29, 2015, the last trading day ... shares reported on the OTCBB was $2.29 per share. , The tender offer will ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  The Dr. ... is now offering a full suite of new ... who,ve had a biopsy, for diagnosing prostate cancer. ... a range of genetic tests for assessing the risk and ... "We,re very excited to now offer these ...
Breaking Biology Technology:R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5
... Dendreon Corporation today announced that Chief Executive Officer, Mitchell ... & Young Entrepreneur Of The Year (R) 2009 ... & Young LLP, the awards program recognizes entrepreneurs who ... performance and personal commitment to their businesses and communities. ...
... /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL ) ... Food and Drug Administration (FDA) that the New Drug ... been accepted for,standard review. The FDA will advise ... Pharmaxis is seeking approval for ...
... DIEGO, May 13 Dr. Feng Lin, Director of ... BMSN) and Entest BioMedical Inc., today stated that he ... injury" (TBI) using autologous "adipose-derived" stem cells represents a ... both Bio-Matrix and Entest BioMedical are now studying the ...
Cached Biology Technology:Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2U.S. FDA Accepts Aridol(TM) New Drug Application for Review 2'Adipose-derived' Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Group's, Entest BioMedical Inc. Researcher 2
(Date:6/16/2015)... 2015 /CNW Telbec/ - handyem Inc. and FlowMetric ... incorporation of handyem,s HPC-150 portable flow cytometer within ... This unprecedented model of mobile laboratory platform is ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue ...
(Date:6/15/2015)... , June 15, 2015 A ... from Telstra reveals the majority of US consumers using mobile ... via biometrics, such as fingerprint and voiceprint, instead of having ... According to Telstra,s " Mobile Identity   -   ... report, with smartphones now the primary channel used by ...
(Date:6/9/2015)... June 9, 2015   MedNet Solutions , an ... spectrum of clinical research, will be providing demonstrations of ... at the 2015 Drug Information Association (DIA) Annual Meeting ... 15-17.  These presentations will include previews of many exciting ... the upcoming iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... avoid cancer of the kidneys, a new major study from ... kinds of fatty fish a few times a month would ... the end of the 1980s, 90,000 Swedish women were sent ... mammography scan. Now, with the help of another questionnaire a ...
... dramatic increase in testicular cancer, now the most ... the focus of a five-year, $5.5 million National ... researcher Tongzhang Zheng. , Testicular cancer is increasing ... important information on possible environmental, genetic and other ...
... have discovered a new, more accurate, method of mapping ... could lead to more effective treatments and prevention of ... Duncan Maskell at the Centre for Veterinary Science, and ... with observational data to predict the spread of individual ...
Cached Biology News:Researchers map spread of pathogens in the human body 2
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: